Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Revenue (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Revenue for 4 consecutive years, with $437602.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 223.45% to $437602.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $943721.0, a 91.96% increase, with the full-year FY2024 number at $607574.0, up 139.61% from a year prior.
  • Revenue was $437602.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $100932.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $437602.0 in Q3 2025 to a low of -$37174.0 in Q4 2022.
  • A 4-year average of $130326.5 and a median of $124972.0 in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 69.56% in 2023, then skyrocketed 515.39% in 2024.
  • 60 Degrees Pharmaceuticals' Revenue stood at -$37174.0 in 2022, then soared by 438.09% to $125681.0 in 2023, then soared by 92.26% to $241635.0 in 2024, then skyrocketed by 81.1% to $437602.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Revenue are $437602.0 (Q3 2025), $100932.0 (Q2 2025), and $163552.0 (Q1 2025).